Viatris Earnings Call Highlights Slow Growth, Cash Strength
Viatris, Inc. ((VTRS)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Viatris’ latest earnings call struck a cautiously optimistic tone as management balanced modest near-term growth with confidence in cash generation and a strengthening late-stage pipeline. Executives acknowledged operational and margin headwinds, but framed 2025–2028 as a transition period toward higher-quality earnings backed by cost savings, regulatory milestones and selective business development.
Steady 2025 Results Anchor the Transition Story
Viatris reported 2025 revenue of $14.3 billion, up about 2% on an operational and divestiture-adjusted basis, providing a stable base for its multi-year plan. Adjusted EBITDA came in at $4.2 billion and adjusted EPS at $2.35, underscoring resilient profitability despite portfolio shifts and regional pricing pressure.
Quarterly Momentum Signals Stable Entry into 2026
Fourth-quarter 2025 revenue reached $3.7 billion, roughly 1% higher year over year on an operational basis. Management highlighted strong commercial execution across key geographies, indicating that the company enters 2026 with underlying demand intact even as certain markets and products face headwinds.
Cash Engine Powers Shareholder Returns and Optionality
The company generated about $2.2 billion of free cash flow in 2025 excluding transaction costs and returned more than $1 billion to shareholders through dividends and buybacks. Management expects over $2.5 billion of deployable cash in 2026, including monetization proceeds, providing capacity for capital returns, bolt-on deals and some debt reduction.
Strategic Review Targets $650 Million in Cost Savings
Following an enterprise-wide review, Viatris outlined a plan to achieve roughly $650 million in gross cost savings over three years, yielding about $400 million in net benefits after up to $250 million of reinvestment. Savings will be phased with about 30% realized in 2026, 30% in 2027 and 40% in 2028, split roughly evenly between headcount cuts and operational efficiencies.
2026 Outlook: Low Single-Digit Growth Across the Portfolio
For 2026, management guided to around 2% growth in both total revenue and adjusted EBITDA versus 2025, signaling another year of incremental progress rather than a breakout. New product revenues are forecast at $450 million to $550 million, with developed markets up 2%, Europe 4%, emerging markets 6%, Greater China 3% and North America flat.
R&D Advances Feed a More Innovative Pipeline
The company reported five positive Phase 3 readouts in 2025 and is advancing several late-stage programs, including cenerimod and Soladragrom, with full enrollment expected in key trials. Enrollment for selatogrel is accelerating at about 1,200 patients per month, and Viatris expects a top-line readout for Nefecon in Japan in the first half of 2026.
Regulatory Milestones Queue Up for 2026 and Beyond
Multiple regulatory decisions are slated for 2026, including a low-dose estrogen weekly patch and a phenylephrine ophthalmic product for presbyopia under review in the United States. In Japan, the company anticipates a decision on EFFEXOR around March and plans pitolisant filings later in the year, alongside a positive pre-filing meeting that clears the way for a fast-acting meloxicam submission.
Targeted Deal-Making Focuses on In-Market Assets
Viatris closed approximately 60 regional business development transactions in 2025, including a notable deal with Aculys Pharma in Japan, underlining its appetite for focused expansion. Management reiterated that future deals will prioritize accretive commercial assets already in the market rather than early-stage, higher-risk R&D acquisitions.
Product Opportunities Aim to Differentiate the Portfolio
Fast-acting meloxicam is positioned for post-operative acute pain with data supporting reduced opioid use, which management expects to be reflected in labeling and to drive uptake. The company also touted sotagliflozin as a potential best-in-class SGLT with cardiovascular benefits and continues the life-cycle program for Influvac High Dose in Europe to defend and grow its vaccines franchise.
India Plant Fire Adds Execution Risk but Limited 2026 Drag
A February fire at the Nashik oral solid dose facility led to a temporary production halt, with a restart targeted beginning in April. Viatris has assumed less than 1% recovery from India in its 2026 guidance after a roughly $325 million revenue hit in 2025, while acknowledging that the timing of a regulatory reinspection remains uncertain.
Margin Pressure Weighs on Near-Term Profitability
Management warned that 2026 gross margins will be modestly lower year over year, reflecting losses of exclusivity, product mix shifts and recovery in lower-margin antiretroviral supply. Additionally, a $40 million transition services income benefit booked in 2025 will not repeat, limiting the visible near-term upside to margin performance.
Restructuring and One-Off Charges Cloud Short-Term Earnings
The strategic overhaul brings an estimated $700 million of one-time charges and transaction-related costs, including taxes tied to divestitures. Roughly $250 million of restructuring cash outlays are expected in 2026, creating short-term pressure on earnings and free cash flow even as management argues the moves are essential to reshape the cost base.
Regional Pricing and LOE Headwinds in Japan and Australia
The JANZ region faces ongoing government-driven price cuts and a mid-year loss of exclusivity for Amitiza in Japan, which are set to weigh on revenue and EBITDA. Management stressed that turning this region around will require careful portfolio repositioning and new launches to offset the structural and policy challenges.
Execution Risk Pushes Upside Potential into Later Years
Viatris acknowledged that several key value drivers depend on regulatory approvals, the successful restart of the India plant and timely product launches. Many strategic assets, such as EFFEXOR in Japan, the low-dose estrogen patch and sotagliflozin, are unlikely to materially lift 2026 results, pushing meaningful financial upside further into the back half of the decade.
Cost Savings Benefits Will Build Gradually, Not Immediately
While the $650 million gross savings plan is central to the story, management emphasized that tangible margin expansion will be gradual, with full run-rate benefits expected by 2029. Headcount reductions take time to execute and cost-of-goods efficiencies are back-end loaded, limiting the near-term earnings boost even as the structural trajectory improves.
Guidance Underscores a Back-Loaded, Cash-Rich Transformation
Viatris’ 2026 guidance points to about 2% revenue and adjusted EBITDA growth on a slightly back-loaded basis, with the first quarter expected to be the weakest for revenue, margin and free cash flow. The company plans to maintain its dividend, pursue accretive deals and some debt paydown to reach roughly 2.8 to 3.2 times gross leverage, underpinned by over $2.5 billion of available cash and a cost program that ramps through 2028.
Viatris’ earnings call painted a picture of a company in controlled transition, trading near-term margin compression and restructuring noise for longer-term efficiency and innovation. For investors, the story hinges on the firm’s ability to deliver on cost savings, regulatory wins and disciplined capital deployment, with the real payoff likely emerging beyond 2026 rather than in the coming year.
